Hostname: page-component-78c5997874-ndw9j Total loading time: 0 Render date: 2024-11-15T13:46:42.708Z Has data issue: false hasContentIssue false

Effect of Two Long-acting Treatments, The Paliperidone Palmitate 1-month and 3-month Formulations on Caregiver Burden in European patients with Schizophrenia

Published online by Cambridge University Press:  23 March 2020

L. Hargarter
Affiliation:
Janssen-Cilag GmbH, Janssen-Cilag GmbH, Neuss, Germany
S. Gopal
Affiliation:
Janssen Research & Development, Central nervous system, Titusville, USA
H. Xu
Affiliation:
Janssen Research & Development, Clinical Biostats, Titusville, USA
K. McQuarrie
Affiliation:
Janssen Research & Development, Hub General, Titusville, USA
A. Savitz
Affiliation:
Janssen Research & Development, Central nervous system, Titusville, USA
I. Nuamah
Affiliation:
Janssen Research & Development, Clinical Biostats, Titusville, USA
K. Woodruff
Affiliation:
Janssen Research & Development, HECOR, Horsham, USA
M. Mathews
Affiliation:
Janssen Research & Development, FRANCHISE AND NBD, Titusville, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Schizophrenia puts a significant burden on caregivers.

Objectives

To explore the effects of two long-acting treatments (LAT), paliperidone palmitate 1-month and 3-month formulations on caregiver burden (CGB) in European patients with schizophrenia using the Involvement Evaluation Questionnaire (IEQ)

Aims

To conduct a subgroup analysis of two randomized, double-blind studies (NCT01515423 and NCT01529515).

Methods

Caregivers (≥ 1 h of contact/week with the patients) were offered to complete the IEQ (31 items, each scoring: 0–4; total score: sum of 27 items [0–108]).

Results

Among 756 European caregivers (53% parents, 18% spouse/partner or girl/boyfriend, 10% sister/brother), 60% reported a CGB of ≥ 32 hours/week at open-label baseline (BL-OL). CGB reduced significantly for patients with both BL-OL and at least one double-blind IEQ sum-score (n = 433): mean improvement [SD] (9.9 [12.66], P < 0.001) from BL-OL (mean [SD] 26.0 [13.30]) to study end (16.0 [10.47]); (reduction in burden associated with worrying [2.9 points] and urging [4.3 points]). CGB significantly improved in patients on prior oral antipsychotics post-switching to LAT with less leisure days impacted and less hours spent in caregiving (P < 0.001). There was significant relationship between improvements and relapse status, patient age (P < 0.001), age at diagnosis (P < 0.002), and number of prior psychiatric hospitalizations in the last 24 months (P < 0.05). Prior use of long-acting antipsychotics other than paliperidone palmitate 1-month or 3-month formulations at BL-OL and duration of prior psychiatric hospitalizations in the last 24 months did not show significant effect on improvements.

Conclusion

Switching from an oral antipsychotic to an LAT can provide a meaningful and significant improvement in caregiver burden.

Disclosure of interest

All authors are employees of Janssen Research & Development, LLC and hold stocks in the company.

Type
e-Poster walk: Schizophrenia and other psychotic disorders–part 2
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.